TAKEDA-SPONSORED
Gastroenterology Scientific Presentations
Presented at the American College of Gastroenterology 2026 Annual Scientific Meeting
October 9 – 14, 2026 | Nashville, TN
Eosinophilic Esophagitis (EoE)
POSTER #2927
Insurance coverage and patient out-of-pocket costs influence physicians in choosing off-label over FDA-approved treatments for patients with eosinophilic esophagitis: Results from a US physician survey
Low E, Goodwin B, Khoja L, Lloyd J, Houpt B, Daniel I, Hughes G (presenting author), Terreri B, Gonsalves NP
Monday Poster Session
October 12, 2026
10:30 AM - 4:15 PM
MCC Level 3, Hall A1 – Hall D
POSTER #5186
Real-world utilization of budesonide oral suspension in patients with eosinophilic esophagitis shows use beyond 12 weeks: A retrospective cohort study of US health insurance claims data
Shah ED (presenting author), Goodwin B, Lee L, Korgaonkar S, Meyers J, Hughes G, Terreri B, Dellon ES
Tuesday Poster Session
October 13, 2026
10:30 AM - 4:00 PM
MCC Level 3, Hall A1 – Hall D
POSTER #5196
Missed opportunities for diagnosis and treatment of eosinophilic esophagitis following acute food impaction and dysphagia events in the USA
Horsley-Silva JL, Goodwin B, Khoja L, Gallivan M, Lam F, Silber A, Hughes G (presenting author), Terreri B, Feuerstadt P
Tuesday Poster Session
October 13, 2026
10:30 AM - 4:00 PM
MCC Level 3, Hall A1 – Hall D
Inflammatory Bowel Disease (IBD)
Poster #1059
Improving real-world corticosteroid exposure estimation in inflammatory bowel disease using large language models
Lin Z, Rosas L, Chavez F, Jimenez Lara D, Basra S, Stanton M, Chou C, Brown J, Sanchirico M, Hanauer SB, Luo Y, Dulai PS (presenting author)
Sunday Poster Session
October 11, 2026
3:30 - 7:00 PM
MCC Level 3, Hall A1 – Hall D
Poster #1146
Vedolizumab versus risankizumab for efficacy outcomes during maintenance treatment in ulcerative colitis: A network meta-analysis and multilevel network meta-regression
Chan K, Zhang I, Brown J, Chou C, Frederickson A, Null K, Sanchirico M, Sleiman J (presenting author), Jairath V, Rieder F
Sunday Poster Session
October 11, 2026
3:30 - 7:00 PM
MCC Level 3, Hall A1 – Hall D
Poster #1162
Real-world assessment of injection experience and treatment satisfaction among patients with inflammatory bowel disease initiating subcutaneous vedolizumab
Ritter TE, Varisco TJ, Gower M, Brown J, Gift T, Hanna KE, Weeks CJ, Van Anglen LJ (presenting author)
Sunday Poster Session
October 11, 2026
3:30 - 7:00 PM
MCC Level 3, Hall A1 – Hall D
Poster #1204
Real‑world comparative outcomes of vedolizumab and ustekinumab in biologic‑naïve and biologic‑experienced patients with Crohn’s disease in the United States and Canada
Deepak P, Yarur A (presenting author), Brett N, Khan Z, Ling Y, Agboton C, Farhat Z, Bressler B
Sunday Poster Session
October 11, 2026
3:30 - 7:00 PM
MCC Level 3, Hall A1 – Hall D
Poster #1205
Real-world effectiveness, treatment patterns, and safety of vedolizumab and ustekinumab in Crohn’s disease: A retrospective chart review in the United States and Canada
Yarur A (presenting author), Deepak P, Brett N, Gianchetti L, Ling Y, Agboton C, Farhat Z, Bressler B
Sunday Poster Session
October 11, 2026
3:30 - 7:00 PM
MCC Level 3, Hall A1 – Hall D
Poster #3336
Treatment persistence of first-line advanced therapies in older adults with ulcerative colitis using US claims data
Afzali A (presenting author), Friderici J, Si Z, Zhao W, Chen Y-H, Munshi K, Gravlee E, Muller B, Wojtowicz AM, Brown J
Monday Poster Session
October 12, 2026
10:30 AM - 4:15 PM
MCC Level 3, Hall A1 – Hall D
Poster #3419
Real-world clinical outcomes of vedolizumab in CD patients with different disease location: Post hoc analysis of the VALUE study
Zhong X, Qian X, Zhou F, Chen M (presenting author)
Monday Poster Session
October 12, 2026
10:30 AM - 4:15 PM
MCC Level 3, Hall A1 – Hall D
Poster #3420
Real-world clinical outcomes of vedolizumab in severe active ulcerative colitis in China: Post hoc VALUE study analysis
Li J, Gu L, Zhou F, Chen M (presenting author)
Monday Poster Session
October 12, 2026
10:30 AM - 4:15 PM
MCC Level 3, Hall A1 – Hall D
Poster #3421
Real-world clinical outcomes of vedolizumab in ulcerative colitis patients by disease extension: Post hoc analysis of the VALUE study
Hao J, Chen H, Gu L, Zhou F, Chen M (presenting author)
Monday Poster Session
October 12, 2026
10:30 AM - 4:15 PM
MCC Level 3, Hall A1 – Hall D
Poster #3422
Real-world outcomes of vedolizumab in CD patients without baseline IBD-related complications: Post hoc results from the VALUE study
Li Y, Qian X, Zhou F, Chen M (presenting author)
Monday Poster Session
October 12, 2026
10:30 AM - 4:15 PM
MCC Level 3, Hall A1 – Hall D
Poster #3435
Treatment persistence of patients with inflammatory bowel disease switching from vedolizumab intravenous to subcutaneous maintenance versus intravenous long-term maintenance: Real-world Canadian cohort data
Horst S (presenting author), Ho A, Moulson R, Yang Z, Pettengell C, Hughes G, Gift T, Brown J, Barfield E, Bressler B
Monday Poster Session
October 12, 2026
10:30 AM - 4:15 PM
MCC Level 3, Hall A1 – Hall D
Poster #3501
AI-enabled inflammatory bowel disease knowledge management layers: Impact of automating scientific work data analysis and validation of outputs for downstream use
Ramesh P (presenting author), Agboton C
Monday Poster Session
October 12, 2026
10:30 AM - 4:15 PM
MCC Level 3, Hall A1 – Hall D
Poster #5664
Onset of action of vedolizumab versus placebo in patients with Crohn’s disease: A post hoc analysis of GEMINI 2, GEMINI 3, VISIBLE 2, and VERSIFY
Hoffman JM, Gift T, Wang J, Robinson I, Uddin S, Kane S (presenting author)
Tuesday Poster Session
October 13, 2026
10:30 AM - 4:00 PM
MCC Level 3, Hall A1 – Hall D
MCC, Music City Center.